Home・Stock List・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Closed

SectorHealthcare

2.29 -1.29

Buy Sell

Overview

Share price change

24h

Current

Min

2.26

Max

2.31

Key metrics
By Trading Economics
Income	14M -1M
Sales	16M 21M
EPS	-0.003
Profit margin	-4.943
Employees	81
EBITDA	15M 657K

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+119.65% upside

Dividends
By Acuity
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	324M 1B
Previous open	3.58
Previous close	2.29

News Sentiment

By Acuity

50%

163 / 340 Healthcare

Lexicon Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Jul 2026, 20:07 UTC

Lexicon Pharmaceuticals Inc shares are lower today, reversing from earlier gains amid broader market volatility influenced by falling oil prices and inflation concerns.

22 Jul 2026, 19:02 UTC

Lexicon Pharmaceuticals Inc shares are lower today, continuing a decline since Tuesday's close. The stock remains below its 20-day moving average.

21 Jul 2026, 19:42 UTC

Lexicon Pharmaceuticals is higher as the market gains momentum, driven by strong performances from major companies and a resurgence in semiconductor stocks.

20 Jul 2026, 19:06 UTC

Lexicon Pharmaceuticals Inc shares are lower today, following three days of gains. Broader market declines are linked to rising US Treasury yields and oil prices above $90.

Peer Comparison

Price change

Lexicon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

119.65% upside

12 Months Forecast

Average 5.03 USD 119.65%

High 6 USD

Low 3.1 USD

Based on 3 Wall Street analysts offering 12 month price targets forLexicon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Lexicon Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

163 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.